BSE Live
Apr 08, 16:01Prev. Close
1202.25
Open Price
1239.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 08, 15:59Prev. Close
1202.40
Open Price
1220.00
Bid Price (Qty.)
1215.90 (195)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Cipla (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,964.31 | 2,492.83 | 1,911.40 | 1,186.94 | 1,743.97 | |
| Net CashFlow From Operating Activities | 2,018.14 | 1,468.05 | 1,116.53 | 2,207.39 | 1,728.40 | |
| Net Cash Used In Investing Activities | -1,126.33 | -1,147.05 | -592.16 | -1,191.25 | -1,205.67 | |
| Net Cash Used From Financing Activities | -693.89 | -473.32 | -350.96 | -1,010.80 | -547.00 | |
| Foreign Exchange Gains / Losses | -0.85 | -0.66 | -0.56 | -0.50 | -0.31 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 197.07 | -152.98 | 172.85 | 4.84 | -24.58 | |
| Cash And Cash Equivalents Begin of Year | 64.47 | 217.45 | 44.60 | 39.76 | 64.34 | |
| Cash And Cash Equivalents End Of Year | 261.54 | 64.47 | 217.45 | 44.60 | 39.76 |
01.04.2026
19.03.2026
04.03.2026
Cipla to form JV with Kemwell Biopharma; share price down marginally
04.03.2026
27.01.2026
Cipla Consolidated December 2025 Net Sales at Rs 7,074.48 crore, up 0.02% Y-o-Y
27.01.2026
Cipla Standalone December 2025 Net Sales at Rs 4,498.08 crore, down 9.51% Y-o-Y
10.11.2025
Cipla Standalone September 2025 Net Sales at Rs 5,225.72 crore, up 9.44% Y-o-Y
03.11.2025
Cipla Consolidated September 2025 Net Sales at Rs 7,589.44 crore, up 7.64% Y-o-Y
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
09.05.2024
17.04.2024
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
12.07.2023
28.01.2025
30.10.2024
Multiple near-term challenges may hijack Cipla's growth trajectory
13.05.2024
06.11.2018
Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
08.04.2026
07.04.2026
Kiran Mazumdar‑Shaw calls for new IPO rules to unlock India’s innovation potential in life sciences
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth